These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 37880479)
1. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Bischof L; Ussmann J; Grimm J; Bill M; Brauer D; Backhaus D; Herrmann L; Merz M; Herling M; Metzeler KH; Franke GN; Vucinic V; Platzbecker U; Schwind S; Jentzsch M Leukemia; 2024 Jan; 38(1):198-201. PubMed ID: 37880479 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902 [TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272 [TBL] [Abstract][Full Text] [Related]
9. Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference? El Chaer F; Ballen KK Bone Marrow Transplant; 2022 Oct; 57(10):1473-1474. PubMed ID: 35902643 [No Abstract] [Full Text] [Related]
10. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909 [TBL] [Abstract][Full Text] [Related]
11. Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia. Shimomura Y; Hara M; Maruoka H; Yabushita T; Ishikawa T Leuk Lymphoma; 2020 Mar; 61(3):745-748. PubMed ID: 31710240 [No Abstract] [Full Text] [Related]
12. Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Rodríguez-Arbolí E; Orvain C; Othus M; Walter RB Bone Marrow Transplant; 2022 Nov; 57(11):1732-1734. PubMed ID: 36030308 [No Abstract] [Full Text] [Related]
13. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162 [TBL] [Abstract][Full Text] [Related]
15. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. Hourigan CS; Dillon LW; Gui G; Logan BR; Fei M; Ghannam J; Li Y; Licon A; Alyea EP; Bashey A; Deeg HJ; Devine SM; Fernandez HF; Giralt S; Hamadani M; Howard A; Maziarz RT; Porter DL; Scott BL; Warlick ED; Pasquini MC; Horwitz ME J Clin Oncol; 2020 Apr; 38(12):1273-1283. PubMed ID: 31860405 [TBL] [Abstract][Full Text] [Related]
16. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. Appelbaum FR Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770 [TBL] [Abstract][Full Text] [Related]
17. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia. Fasan O Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019 [TBL] [Abstract][Full Text] [Related]
18. Positive Minimal Residual Disease of FLT3-ITD before Hematopoietic Stem Cell Transplantation Resulted in a Poor Prognosis of an Acute Myeloid Leukemia. Iwasaki Y; Nishiuchi R; Aoe M; Takahashi T; Watanabe H; Tokorotani C; Kikkawa K; Shimada A Acta Med Okayama; 2017 Feb; 71(1):79-83. PubMed ID: 28238014 [TBL] [Abstract][Full Text] [Related]
19. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089 [TBL] [Abstract][Full Text] [Related]
20. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Orvain C; Wilson JA; Fang M; Sandmaier BM; Rodríguez-Arbolí E; Wood BL; Othus M; Appelbaum FR; Walter RB Haematologica; 2023 Feb; 108(2):420-432. PubMed ID: 35924583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]